These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 38820324)
1. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data. Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324 [TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
3. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children. Wesseling-Perry K; Salusky IB Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010 [TBL] [Abstract][Full Text] [Related]
4. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640 [TBL] [Abstract][Full Text] [Related]
5. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm. Rastogi A; Bhatt N; Rossetti S; Beto J J Ren Nutr; 2021 Jan; 31(1):21-34. PubMed ID: 32386937 [TBL] [Abstract][Full Text] [Related]
6. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels. Haffner D; Leifheit-Nestler M Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044 [TBL] [Abstract][Full Text] [Related]
7. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure. Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180 [TBL] [Abstract][Full Text] [Related]
8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
9. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389 [TBL] [Abstract][Full Text] [Related]
10. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients. Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995 [TBL] [Abstract][Full Text] [Related]
11. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice. Shastri J; Tran A; Covit A; Pepe J; Sherman RA J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302 [TBL] [Abstract][Full Text] [Related]
12. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646 [TBL] [Abstract][Full Text] [Related]
13. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE; Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079 [TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis. Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691 [TBL] [Abstract][Full Text] [Related]
15. Phosphate control in reducing FGF23 levels in hemodialysis patients. Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150 [TBL] [Abstract][Full Text] [Related]
16. Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease. Bellorin-Font E; Vasquez-Rios G; Martin KJ Curr Osteoporos Rep; 2019 Oct; 17(5):333-342. PubMed ID: 31485996 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Qunibi WY; Nolan CA; Ayus JC Kidney Int Suppl; 2002 Dec; (82):S73-80. PubMed ID: 12410860 [TBL] [Abstract][Full Text] [Related]
18. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Terai K; Nara H; Takakura K; Mizukami K; Sanagi M; Fukushima S; Fujimori A; Itoh H; Okada M Br J Pharmacol; 2009 Apr; 156(8):1267-78. PubMed ID: 19302594 [TBL] [Abstract][Full Text] [Related]
19. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618 [TBL] [Abstract][Full Text] [Related]
20. [Renal osteodystrophy (3); its treatment in dialysis patients]. Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]